Fludarabine: all 769 studies that test it

Page 3 of 8. Open to participants first (148), then studies with results posted, then the rest; newest registration first within each.

• T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated CancersCompletedNCT02280811Phase 1/2Results posted
• JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisCompletedNCT02251821Phase 2Results posted
• A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02251548Phase 2Results posted
• Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic AnemiaCompletedNCT02224872Phase 2Results posted
• Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple MyelomaCompletedNCT02215967Phase 1Results posted
• Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative RegimenTerminatedNCT02199041Phase 2Results posted
• A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLLActive, not recruitingNCT02158091Phase 1/2Results posted
• Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic DiseasesTerminatedNCT02145039Not applicableResults posted
• AML Therapy With Irradiated Allogeneic CellsTerminatedNCT02105116Not applicableResults posted
• Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)TerminatedNCT02080195Phase 1/2Results posted
• Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and MyelodysplasiaCompletedNCT02007863Not applicableResults posted
• Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic LeukemiaCompletedNCT01991457Phase 2Results posted
• Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT01904136Phase 1/2Results posted
• Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT01898793Phase 1/2Results posted
• Stem Cell Transplantation for Sickle Cell AnemiaCompletedNCT01877837Phase 3Results posted
• Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in ChildrenCompletedNCT01858740Phase 2Results posted
• Non-Myeloablative Conditioning and Bone Marrow TransplantationActive, not recruitingNCT01850108Not applicableResults posted
• Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic LeukemiaCompletedNCT01824693Phase 2Results posted
• Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesCompletedNCT01823198Phase 1/2Results posted
• Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord TransplantationCompletedNCT01810588Phase 2Results posted
• Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic MalignancyCompletedNCT01807611Phase 2Results posted
• Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic MelanomaCompletedNCT01807182Phase 2Results posted
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic MalignanciesCompletedNCT01760655Phase 2Results posted
• Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow TransplantationTerminatedNCT01749293Phase 2Results posted
• Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus LenalidomideCompletedNCT01723839Phase 2Results posted
• CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid MalignanciesCompletedNCT01664910Phase 1/2Results posted
• Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell TransplantTerminatedNCT01640301Phase 1/2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Crohn's Allogeneic Transplant StudyTerminatedNCT01570348Phase 2Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01527045Phase 2Results posted
• Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic MalignanciesCompletedNCT01499147Not applicableResults posted
• Allogeneic Hematopoietic Stem Cell Transplantation for Multiple MyelomaCompletedNCT01453101Phase 2Results posted
• Autologous Stem Cell Systemic Sclerosis Immune Suppression TrialTerminatedNCT01445821Phase 3Results posted
• High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell LymphomaTerminatedNCT01434472Phase 2Results posted
• Allogeneic Transplant in HIV Patients (BMT CTN 0903)CompletedNCT01410344Phase 2Results posted
• Reduced Intensity Double Umbilical Cord Blood TransplantationCompletedNCT01408563Phase 2Results posted
• Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATGCompletedNCT01390402Phase 2Results posted
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted
• Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body IrradiationTerminatedNCT01366612Phase 3Results posted
• Treatment of Sickle Cell Anemia With Stem Cell TransplantTerminatedNCT01350232Not applicableResults posted
• Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)TerminatedNCT01339910Phase 3Results posted
• A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic LeukemiaCompletedNCT01292603Phase 1Results posted
• Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic SyndromeCompletedNCT01289457Phase 1/2Results posted
• A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic StatusTerminatedNCT01283386Phase 4Results posted
• A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell DiseaseTerminatedNCT01279616Phase 2Results posted
• Drosophila-generated CTLTerminatedNCT01271907Phase 2Results posted
• A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic StatusTerminatedNCT01271010Phase 4Results posted
• A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic LeukemiaCompletedNCT01263704Phase 2Results posted
• Umbilical Cord Blood Transplant for Children With Myeloid Hematological MalignanciesCompletedNCT01247701Not applicableResults posted
• A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic AnemiaCompletedNCT01187017Phase 1/2Results posted
• Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin LymphomaTerminatedNCT01186458Phase 2Results posted
• Tandem Auto-Allo Transplant for LymphomaCompletedNCT01181271Phase 2Results posted
• Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLLTerminatedNCT01173679Phase 2Results posted
• Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid LeukemiaCompletedNCT01168219Phase 2Results posted
• Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic CancersTerminatedNCT01135329Phase 2Results posted
• Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte InfusionsCompletedNCT01131169Phase 2Results posted
• HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic MalignanciesCompletedNCT01119066Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantTerminatedNCT01118013Phase 2Results posted
• Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)CompletedNCT01096992Phase 1/2Results posted
• Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01082939Phase 2Results posted
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01028716Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01027000Phase 2Results posted
• Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT01019317Phase 2Results posted
• Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT01008462Phase 2Results posted
• Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic CancerTerminatedNCT00963872Phase 1/2Results posted
• Umbilical Cord Blood Transplant for Congenital Pediatric DisordersCompletedNCT00950846Not applicableResults posted
• Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic MalignanciesCompletedNCT00943319Phase 1/2Results posted
• Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic CancerTerminatedNCT00924287Phase 1/2Results posted
• Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell LeukemiaCompletedNCT00924170Phase 1/2Results posted
• Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMACCompletedNCT00923364Phase 2Results posted
• Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00918723Phase 1/2Results posted
• Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHDTerminatedNCT00914940Phase 2Results posted
• Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic LeukemiaCompletedNCT00860574Phase 2Results posted
• Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT00860457Phase 2Results posted
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
• Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic CancerTerminatedNCT00827099Phase 2Results posted
• Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and ThymoglobulinCompletedNCT00822770Phase 1/2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic CancerTerminatedNCT00818961Phase 2Results posted
• Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCYCompletedNCT00809276Phase 1/2Results posted
• Double Cord Blood Transplant for Patients With Malignant and Non-malignant DisordersTerminatedNCT00801931Phase 1/2Results posted
• Busulfan and Fludarabine Followed by Post-transplant CyclophosphamideCompletedNCT00800839Phase 2Results posted
• Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood TransplantCompletedNCT00796068Phase 2Results posted
• Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic MalignanciesCompletedNCT00795132Phase 2Results posted
• Fludarabine, Cyclophosphamide, and Rituximab - High Dose FrontlineCompletedNCT00794820Phase 2Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerCompletedNCT00789776Phase 1/2Results posted
• Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological CancerCompletedNCT00787761Phase 2Results posted
• Allogeneic Transplantation For Severe OsteopetrosisCompletedNCT00775931Phase 2/3Results posted
• Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT00759798Phase 2Results posted
• Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic MalignanciesCompletedNCT00741455Not applicableResults posted
• Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to TherapyCompletedNCT00727415Phase 1/2Results posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerCompletedNCT00723099Phase 2Results posted
• Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell MalignanciesTerminatedNCT00714259Phase 2/3Results posted
• Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)TerminatedNCT00684255Phase 1Results posted
• T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00683046Phase 2Results posted
• Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi AnemiaCompletedNCT00630253Phase 1/2Results posted
• Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT00629798Phase 2Results posted
• Allogeneic Hematopoietic Cell Transplantation for Severe Systemic SclerosisCompletedNCT00622895Phase 1/2Results posted
• Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic CancersCompletedNCT00619645Phase 2Results posted
• Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell HistiocytosisTerminatedNCT00618540Phase 2Results posted

← Fludarabine overview